Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Andrew Bodiford, Mahsa S Talbott & Nishitha M Reddy. (2015) Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations. Blood and Lymphatic Cancer: Targets and Therapy 5, pages 109-114.
Read now
Read now
Andrew Bodiford, Megan Bodge, Mahsa S Talbott & Nishitha M Reddy. (2014) Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. OncoTargets and Therapy 7, pages 1971-1977.
Read now
Read now
Articles from other publishers (30)
Min Li, Huijuan Yu, Yiran Li, Xin Li, Shiqing Huang, Xiaogang Liu, Gaoqi Weng, Lei Xu, Tingjun Hou, Dong-Sheng Guo & Yi Wang. (2023) Rational design of supramolecular self-assembly sensor for living cell imaging of HDAC1 and its application in high-throughput screening. Biosensors and Bioelectronics 242, pages 115716.
Crossref
Crossref
Bo Han, Mengfei Wang, Jiayi Li, Qiushi Chen, Niubing Sun, Xuezhi Yang & Qingwei Zhang. (2023) Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases. European Journal of Medicinal Chemistry 258, pages 115613.
Crossref
Crossref
Yi Dai, Yang Zhang, Tianxiang Ye & Yue Chen. (2023) Synthesis and Antitumor Evaluation of Biotin-SN38-Valproic Acid Conjugates. Molecules 28:9, pages 3936.
Crossref
Crossref
Zhonghua Li, Ruiling Ouyang, Yuechao Cao, Dandan Han, Songgu Wu & Junbo Gong. (2022) Solubility Enhancement of Anticancer Drug Belinostat via the Co-crystallization Strategy: Synthesis, Characterization, and Antitumor Activity In Vitro Evaluation. Crystal Growth & Design 23:2, pages 792-800.
Crossref
Crossref
Shashank Kumar & Abhay Kumar Pandey. (2023) Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma. Current Oncology 30:2, pages 1363-1380.
Crossref
Crossref
Jemma Arakelyan, Daniil A. Rusanov, Meng Rui Chang, Aleksandra V. Asaturova, Galina S. Kireeva, Mana Alshehri, Wee Han Ang & Maria V. Babak. (2023) Targeting emerging cancer hallmarks by transition metal complexes: Epigenetic reprogramming and epitherapies. Part II. Coordination Chemistry Reviews 475, pages 214899.
Crossref
Crossref
Davide Bonanni, Andrea Citarella, Davide Moi, Luca Pinzi, Elisa Bergamini & Giulio Rastelli. (2022) Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90). Current Medicinal Chemistry 29:9, pages 1474-1502.
Crossref
Crossref
Moran Sun, Jinling Qin, Yingying Kang, Yixin Zhang, Mengyu Ba, Hua Yang, Yongtao Duan & Yongfang Yao. (2022) 2-Methoxydiol derivatives as new tubulin and HDAC dual-targeting inhibitors, displaying antitumor and antiangiogenic response. Bioorganic Chemistry 120, pages 105625.
Crossref
Crossref
Jie Wang, Zhuoxian Cao, Fang Wang, Pan Wang, Jianxiong An, Xiaozhong Fu, Ting Liu, Yan Li, Yongjun Li, Yonglong Zhao, Hening Lin & Bin He. (2021) Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer. European Journal of Medicinal Chemistry 225, pages 113799.
Crossref
Crossref
Lingyue Gao, Zhuo-Xun Wu, Yehuda G. Assaraf, Zhe-Sheng Chen & Lihui Wang. (2021) Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resistance Updates 57, pages 100770.
Crossref
Crossref
Manpreet Kaur, Loveleen & Raj Kumar. (2020) Inhibition of histone deacetylases, topoisomerases and epidermal growth factor receptor by metal-based anticancer agents: Design & synthetic strategies and their medicinal attributes. Bioorganic Chemistry 105, pages 104396.
Crossref
Crossref
Yefang Zou, Zhuoxian Cao, Jie Wang, Xiaoxue Chen, Yan-qin Chen, Yan Li, Jingzi Liu, Yonglong Zhao, Aimin Wang & Bin He. (2020) A Series of Novel HDAC Inhibitors with Anthraquinone as a Cap Group. Chemical and Pharmaceutical Bulletin 68:7, pages 613-617.
Crossref
Crossref
Jeremy D. Osko & David W. Christianson. (2020) Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6. Bioorganic & Medicinal Chemistry Letters 30:8, pages 127023.
Crossref
Crossref
Hamam & Palaniyar. (2019) Post-Translational Modifications in NETosis and NETs-Mediated Diseases. Biomolecules 9:8, pages 369.
Crossref
Crossref
Fang Wang, Chun Wang, Jie Wang, Yefang Zou, Xiaoxue Chen, Ting Liu, Yan Li, Yonglong Zhao, Yongjun Li & Bin He. (2019)
N
ɛ
-acetyl lysine derivatives with zinc binding groups as novel HDAC inhibitors
. Royal Society Open Science 6:6, pages 190338.
Crossref
Crossref
Yan Li, Fang Wang, Xiaoxue Chen, Jie Wang, Yonglong Zhao, Yongjun Li & Bin He. (2019) Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups. Current Topics in Medicinal Chemistry 19:3, pages 223-241.
Crossref
Crossref
Aikaterini Giannopoulou, Athanassios Velentzas, Eumorphia Konstantakou, Margaritis Avgeris, Stamatia Katarachia, Nikos Papandreou, Nikolas Kalavros, Vassiliki Mpakou, Vassiliki Iconomidou, Ema Anastasiadou, Ioannis Kostakis, Issidora Papassideri, Gerassimos Voutsinas, Andreas Scorilas & Dimitrios Stravopodis. (2019) Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. International Journal of Molecular Sciences 20:6, pages 1291.
Crossref
Crossref
Mei Yang, Xuefei Dang, Yue Tan, Meixing Wang, Xiaojing Li & Gang Li. (2018) I-7ab inhibited the growth of TNBC cells via targeting HDAC3 and promoting the acetylation of p53. Biomedicine & Pharmacotherapy 99, pages 220-226.
Crossref
Crossref
Qing Zhang, Yifan Dai, Zhiming Cai & Lisha Mou. (2018) HDAC Inhibitors: Novel Immunosuppressants for Allo- and Xeno- Transplantation. ChemistrySelect 3:1, pages 176-187.
Crossref
Crossref
Danqi Chen, Aijun Shen, Guanghua Fang, Hongchun Liu, Minmin Zhang, Shuai Tang, Bing Xiong, Lanping Ma, Meiyu Geng & Jingkang Shen. (2016) Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer. Acta Pharmaceutica Sinica B 6:1, pages 93-99.
Crossref
Crossref
Jonas Ecker, Ina Oehme, Ralph Mazitschek, Andrey Korshunov, Marcel Kool, Thomas Hielscher, Judit Kiss, Florian Selt, Carina Konrad, Marco Lodrini, Hedwig E Deubzer, Andreas von Deimling, Andreas E Kulozik, Stefan M Pfister, Olaf Witt & Till Milde. (2015) Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathologica Communications 3:1.
Crossref
Crossref
Constantinos Giaginis, Christos Damaskos, Ioannis Koutsounas, Adamantia Zizi-Serbetzoglou, Nicolaos Tsoukalas, Efstratios Patsouris, Gregorios Kouraklis & Stamatios Theocharis. (2015) Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival. BMC Gastroenterology 15:1.
Crossref
Crossref
Shaliny Ramachandran, Jonathan Ient, Eva-Leonne Göttgens, Adam Krieg & Ester Hammond. (2015) Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia. Genes 6:4, pages 935-956.
Crossref
Crossref
Nicola Chessum, Keith Jones, Elisa Pasqua & Michael Tucker. 2015.
1
63
.
Xiu Shan, Yuan-Shan Fu, Faisal Aziz, Xiao-Qi Wang, Qiu Yan & Ji-Wei Liu. (2014) Ginsenoside Rg3 Inhibits Melanoma Cell Proliferation through Down-Regulation of Histone Deacetylase 3 (HDAC3) and Increase of p53 Acetylation. PLoS ONE 9:12, pages e115401.
Crossref
Crossref
Anish Thomas, Arun Rajan, Eva Szabo, Yusuke Tomita, Corey A. Carter, Barbara Scepura, Ariel Lopez-Chavez, Min-Jung Lee, Christophe E. Redon, Ari Frosch, Cody J. Peer, Yuanbin Chen, Richard Piekarz, Seth M. Steinberg, Jane B. Trepel, William D. Figg, David S. Schrump & Giuseppe Giaccone. (2014) A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. Clinical Cancer Research 20:21, pages 5392-5402.
Crossref
Crossref
Constantinos Giaginis, Paraskevi Alexandrou, Ioanna Delladetsima, Ioanna Giannopoulou, Efstratios Patsouris & Stamatios Theocharis. (2013) Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions. Tumor Biology 35:1, pages 61-71.
Crossref
Crossref
Mette Munk Jensen, Kamille Dumong Erichsen, Camilla Bardram Johnbeck, Fredrik Bj?rkling, Jacob Madsen, Peter Buhl Jensen, Maxwell Sehested, Liselotte H?jgaard & Andreas Kj?r. (2013) [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. BMC Cancer 13:1.
Crossref
Crossref
Fiona Wightman, Hao K. Lu, Ajantha E. Solomon, Suha Saleh, Andrew N. Harman, Anthony L. Cunningham, Lachlan Gray, Melissa Churchill, Paul U. Cameron, Anthony E. Dear & Sharon R. Lewin. (2013) Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS 27:18, pages 2853-2862.
Crossref
Crossref
James P. Parker, Hassan Nimir, Darren M. Griffith, Brian Duff, Anthony J. Chubb, Marian P. Brennan, Maria P. Morgan, Denise A. Egan & Celine J. Marmion. (2013) A novel platinum complex of the histone deacetylase inhibitor belinostat: Rational design, development and in vitro cytotoxicity. Journal of Inorganic Biochemistry 124, pages 70-77.
Crossref
Crossref